EP2637684A4 - Gepufferte ophthalmische zusammensetzungen und verwendungsverfahren dafür - Google Patents

Gepufferte ophthalmische zusammensetzungen und verwendungsverfahren dafür

Info

Publication number
EP2637684A4
EP2637684A4 EP11840613.1A EP11840613A EP2637684A4 EP 2637684 A4 EP2637684 A4 EP 2637684A4 EP 11840613 A EP11840613 A EP 11840613A EP 2637684 A4 EP2637684 A4 EP 2637684A4
Authority
EP
European Patent Office
Prior art keywords
methods
ophthalmic compositions
buffered ophthalmic
buffered
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11840613.1A
Other languages
English (en)
French (fr)
Other versions
EP2637684A2 (de
Inventor
Tamar Tennenbaum
Liora Braiman-Wiksman
Yuval Sagiv
Ofra Levy-Hacham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ARAVA BIO-TECH LTD.
Original Assignee
Healor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healor Ltd filed Critical Healor Ltd
Priority to EP15167715.0A priority Critical patent/EP2944319A1/de
Publication of EP2637684A2 publication Critical patent/EP2637684A2/de
Publication of EP2637684A4 publication Critical patent/EP2637684A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP11840613.1A 2010-11-08 2011-11-08 Gepufferte ophthalmische zusammensetzungen und verwendungsverfahren dafür Withdrawn EP2637684A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP15167715.0A EP2944319A1 (de) 2010-11-08 2011-11-08 Ophthalmische gepufferte zusammensetzungen und verwendung davon

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41146410P 2010-11-08 2010-11-08
US41146610P 2010-11-08 2010-11-08
PCT/IL2011/000866 WO2012063237A2 (en) 2010-11-08 2011-11-08 Buffered ophthalmic compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP15167715.0A Division EP2944319A1 (de) 2010-11-08 2011-11-08 Ophthalmische gepufferte zusammensetzungen und verwendung davon

Publications (2)

Publication Number Publication Date
EP2637684A2 EP2637684A2 (de) 2013-09-18
EP2637684A4 true EP2637684A4 (de) 2014-05-07

Family

ID=46051349

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15167715.0A Withdrawn EP2944319A1 (de) 2010-11-08 2011-11-08 Ophthalmische gepufferte zusammensetzungen und verwendung davon
EP11840613.1A Withdrawn EP2637684A4 (de) 2010-11-08 2011-11-08 Gepufferte ophthalmische zusammensetzungen und verwendungsverfahren dafür

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP15167715.0A Withdrawn EP2944319A1 (de) 2010-11-08 2011-11-08 Ophthalmische gepufferte zusammensetzungen und verwendung davon

Country Status (8)

Country Link
US (2) US20120264681A1 (de)
EP (2) EP2944319A1 (de)
JP (1) JP2013543862A (de)
CN (2) CN103249429A (de)
AU (1) AU2011327785A1 (de)
CA (1) CA2812164A1 (de)
RU (1) RU2013117209A (de)
WO (1) WO2012063237A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
ES2553827T3 (es) 2009-05-01 2015-12-14 Aerie Pharmaceuticals, Inc. Inhibidores de mecanismo doble para el tratamiento de enfermedad
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP2944319A1 (de) 2010-11-08 2015-11-18 Arava Bio-Tech Ltd. Ophthalmische gepufferte zusammensetzungen und verwendung davon
US20130296250A1 (en) * 2011-01-11 2013-11-07 Healor Ltd. Method for treatment of psoriasis
WO2014160371A1 (en) 2013-03-13 2014-10-02 Eleven Biotherapeutics, Inc. Chimeric cytokine formulations for ocular delivery
CA2905089C (en) 2013-03-15 2023-06-13 Aerie Pharmaceuticals, Inc. Isoquinoline compounds for the treatment of ocular diseases
AU2014259948B2 (en) * 2013-04-30 2019-04-18 University Of Southern California Accelerated healing of eye injuries by angiotensin peptides
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
AU2015336396B2 (en) * 2014-10-22 2020-12-10 HLB Therapeutics Co., Ltd. Composition containing thymosin beta 4, and pharmaceutical formulation comprising same
EP3011959A1 (de) 2014-10-23 2016-04-27 Santen SAS Quaternäre Ammoniumverbindung zur Verwendung als Proteinkinase-C-Alpha-Hemmer
CN104940904A (zh) * 2015-05-27 2015-09-30 北京爱特普科技有限公司 一种腔体粘膜微生态调节剂及其制备方法
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR20170021667A (ko) * 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
AU2016332966A1 (en) 2015-09-28 2018-04-26 Azura Ophthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
MX2018012390A (es) 2016-04-14 2019-07-04 Azura Ophthalmics Ltd Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio.
JP6943707B2 (ja) * 2016-08-23 2021-10-06 積水化学工業株式会社 水溶性樹脂組成物及び水溶性樹脂フィルム
EP3506890A1 (de) 2016-08-31 2019-07-10 Aerie Pharmaceuticals, Inc. Ophthalmische zusammensetzungen
US10918699B2 (en) * 2017-03-22 2021-02-16 Michael C. Struck Therapeutic treatment for neurotrophic keratopathy
EP3609871A4 (de) 2017-03-31 2021-01-06 Aerie Pharmaceuticals, Inc. Aryl-cyclopropyl-amino-isochinolinyl-amidverbindungen
CA3112391A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
AU2020224106A1 (en) * 2019-02-20 2021-09-09 Eleos Pharmaceuticals, Llc Topical composition for improved healing of ocular ailments
US10799481B1 (en) 2019-05-06 2020-10-13 Rvl Pharmaceuticals, Inc. Compositions and methods for treating ocular disorders
EP4087655A4 (de) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd Anweisungen für zusammensetzung und empfindlichkeit
CN111610334A (zh) * 2020-05-18 2020-09-01 山东省肿瘤防治研究院（山东省肿瘤医院） 一种基于细胞大小过滤识别肿瘤患者外周血循环肿瘤细胞的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048675A2 (en) * 2006-10-20 2008-04-24 Celldex Therapeutics, Inc. Treatment for age-related macular degeneration and other diseases of the eye

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549747A (en) 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3856919A (en) 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3947573A (en) 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3767788A (en) 1970-06-08 1973-10-23 Burton Parsons Chemicals Inc Ophthalmic solution
US3767789A (en) 1971-06-21 1973-10-23 Burton Parsons & Co Inc Method of providing a synthetic mucus in vivo
US3987163A (en) 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US3907985A (en) 1973-07-27 1975-09-23 Burton Parsons And Company Inc Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US3920810A (en) 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4120949A (en) 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
IL80298A (en) 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
CA2125060C (en) 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JP3059092B2 (ja) * 1995-11-15 2000-07-04 田辺製薬株式会社 ドライアイおよびドライアイを原因とする疾患の予防・治療剤
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
CN101850108A (zh) * 2003-07-15 2010-10-06 巴尔-伊兰大学 用于愈合创伤的方法和药物组合物
NZ545086A (en) * 2003-08-07 2011-06-30 Healor Ltd Pharmaceutical compositions and methods for accelerating wound healing
CA2625674C (en) * 2005-08-29 2015-04-14 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
ITMI20052036A1 (it) * 2005-10-26 2007-04-27 Professional Dietetics Srl Composizioni farmaceutiche oftalmiche a base di amminoacidi e sodio ialuronato
US20080292726A1 (en) * 2007-01-23 2008-11-27 Bernstein Lawrence R Ophthalmic gallium compositions and methods of their use
WO2008137118A1 (en) * 2007-05-04 2008-11-13 The Board Of Trustees Of The Leland Stanford Junior University Suppression of inflammation associated with transplantation using an epsilon pkc inhibitor
KR20130121678A (ko) * 2007-07-30 2013-11-06 힐로 리미티드 약제학적 조성물 및 관련 방법
CA2698013A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
CN102066402B (zh) * 2008-06-19 2013-11-06 学校法人近畿大学 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物
WO2010029350A1 (en) * 2008-09-09 2010-03-18 University Of East Anglia Treatment of fibrotic eye disorders
CN102724994A (zh) * 2010-01-11 2012-10-10 希尔洛有限公司 用于治疗炎性疾病和病症的方法
EP2944319A1 (de) 2010-11-08 2015-11-18 Arava Bio-Tech Ltd. Ophthalmische gepufferte zusammensetzungen und verwendung davon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008048675A2 (en) * 2006-10-20 2008-04-24 Celldex Therapeutics, Inc. Treatment for age-related macular degeneration and other diseases of the eye

Also Published As

Publication number Publication date
US20120264681A1 (en) 2012-10-18
JP2013543862A (ja) 2013-12-09
CA2812164A1 (en) 2012-05-18
CN103249429A (zh) 2013-08-14
WO2012063237A2 (en) 2012-05-18
EP2944319A1 (de) 2015-11-18
US20150094260A1 (en) 2015-04-02
RU2013117209A (ru) 2014-10-27
CN104758921A (zh) 2015-07-08
EP2637684A2 (de) 2013-09-18
AU2011327785A1 (en) 2013-03-07
WO2012063237A3 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
EP2637684A4 (de) Gepufferte ophthalmische zusammensetzungen und verwendungsverfahren dafür
IL250824A0 (en) Certain amino-pyrimidines, their assemblies, and methods of using them
IL247595A0 (en) New modulators and methods of use
EP2536756A4 (de) Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren
EP2584897A4 (de) Resveratrolhaltige zusammensetzungen und verfahren zu ihrer verwendung
EP2611413A4 (de) Hautzusammensetzungen und verwendungsverfahren dafür
SG10201602752XA (en) Melanin modification compositions and methods of use
EP2675471A4 (de) Mit hsa zusammenhängende zusammensetzungen und verwendungsverfahren
EP2596112A4 (de) Acetycystein-zusammensetzungen und verwendungsverfahren dafür
IL225227A0 (en) Preparations including fulvestrant and methods of use
EP2603201A4 (de) Liposomzusammensetzungen und verwendungsverfahren dafür
EP2408302A4 (de) Ophthalmische formulierungen aus ketotifen und verfahren zu ihrer verwendung
EP2437743A4 (de) Ophthalmische formulierungen aus fluticason und verfahren zu ihrer verwendung
SG10201601792UA (en) Novel modulators and methods of use
EP2536283A4 (de) Phenylheteroarylderivate und verwendungsverfahren dafür
EP2667889A4 (de) Wnt-zusammensetzungen und verwendungsverfahren dafür
EP2547340A4 (de) Ophthalmische formulierungen aus cetirizin und verfahren zu ihrer verwendung
ZA201402758B (en) Brimonidine gel compositions and methods of use
HK1189501A1 (zh) 抗體組合物及使用方法
EP2603221A4 (de) Ggf2 und verfahren zu seiner anwendung
EP2622029A4 (de) Druckfarbenentfernungszusammensetzungen und verfahren zu ihrer verwendung
ZA201302952B (en) Fungicidal compositions and methods of use
EP2566485A4 (de) Immunstimulationszusammensetzungen und verwendungsverfahren dafür
HK1166953A1 (en) Compositions and methods of use
GB2478317B (en) Herbicidal composition and method of use thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130605

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140408

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/55 20060101AFI20140402BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ARAVA BIO-TECH LTD.

17Q First examination report despatched

Effective date: 20150126

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150602